FOLH1 and Familial prostate cancer: Ga‐68‐PSMA‐11 in High‐Risk Prostate Cancer Trial: An open‐label, single‐arm, rater‐blinded, multicenter phase 1/2 study to assess safety and diagnostic accuracy and radiotherapeutic implications of pre‐operative Ga‐68‐PSMA‐11 PET/CT imaging in comparison to histopathology, in newly‐diagnosed prostate cancer (PCA) patients at high risk for metastasis, scheduled for radical prostatectomy (RP) with extended pelvic lymph node dissection (EPLND).